GENE ONLINE|News &
Opinion
Blog

2020-04-11| Asia-PacificCOVID-19

Chugai Initiates Actemra’s Phase 3 COVID-19 Trials in Japan

by GeneOnline
Share To

Recently, the USFDA approved phase 3 trials to evaluate the repurposed rheumatoid arthritis drug, Actemra in treating adult patients with severe COVID-19 pneumonia. Roche’s strategic partner, Chugai now follows suit in Japan.

Actemra is a recombinant, humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. It is the world’s first anti-IL-6 receptor antibody created in Japan and is originally prescribed for patients suffering from rheumatoid arthritis, Takayasu arteritis, and giant cell arteritis. Several studies and clinical reports have indicated that an over-activation of the immune response could be a major factor responsible for COVID-19 severity in patients. This phenomenon, known as the cytokine storm, is characterized by the increase of cytokines such as IL-2, IL-6, IL-10, etc. Besides, an elevated level of IL-6 has been associated with the need for mechanical ventilation. Due to this reason, Actemra is chosen as one of the potential candidates against the SARS-CoV-2 virus and is anticipated to benefit victims.

On March 23rd, Genentech, a member of the Roche group was approved by the FDA to conduct a double-blind, placebo-controlled Phase 3 clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate the drug safety and efficacy of Actemra in patients with severe COVID-19 pneumonia. Now Japanese drug manufacturer, Chugai Pharmaceutical Co Ltd., a strategic partner of Roche has also announced plans to initiate phase 3 trials for Actemra in Japan. Chugai has filed a clinical trial notification with the Pharmaceuticals and Medical Devices Agency.

Scientists around the globe are confronting the COVID-19 challenge through multiple approaches. That includes the development and manufacture of COVID-19 detection kits, antibodies, vaccine candidates, convalescent plasma therapy and antivirals like remdesivir, kaletra (lopinavir/ritonavir) and favipiravir among others. Along the same lines, many repurposed drugs like Actemra, anti-malarial drug hydroxychloroquine, Asthma drug Alvesco, and anti-parasitic drug Ivermectin have shown early promise. Multiple clinical trials are currently ongoing around the world to test the efficacy of these candidates in treating COVID-19 patients. It remains to be seen, how many of them will turn out to be fruitful.

Related Article: Amgen, Adaptive Biotechnologies Collaborate to Strengthen COVID-19 Fight

References
  1. https://www.chugai-pharm.co.jp/english/news/detail/20200324093000_711.html
  2. https://www.chugai-pharm.co.jp/news/detail/20200408170000_969.html
  3. https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v1
  4. https://www.medrxiv.org/content/10.1101/2020.03.30.20048058v1

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
Roche’s Gantenerumab Fails Trials In Alzheimer’s Disease
2022-11-15
LATEST
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Scientists Identify New Genetic Variant Related to Obesity
2022-12-01
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
FDA Revokes Authorization Of Eli Lilly’s COVID-19 Antibody
2022-12-01
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
2022-11-30
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
2022-11-30
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!